Thank you, Good Rob. morning.
and another continued demonstrating robust patients confidence Growth had outlook. of we reflecting was year portfolio for GARDASIL oncology, in growth, headwinds strong innovative offset we our the our demonstrate our demand noted, by product to our of driven launches, give serve. strength us products and the Rob new China. importance of Health which the These business in Animal and more the results than As
the pipeline enables Our commercial for innovations in invest operational in deliver value our term execution and and deliver short the us long new to we while term.
X% Now basis. turning quarter Total fourth were impact X% The increase foreign be the following ex exchange to an of revenue on revenues company billion, our of or an results. comments exchange. will excluding $XX.X
sustained with sales driven increasing Our Human primarily by X% oncology. Health momentum business its
performance Animal growth strong business of XX%. Health with Our also delivered sales
earlier-stage Argentina high-risk, the compelling non-small triple-negative growth including by XX% performance Turning sales from billion our as as the increased was indications all KEYNOTE-AXX triple-negative early-stage, In disease. to lung KEYNOTE-XXX.
In demand in continued based advanced resectable U.S., as of as uptake in metastatic cancers. breast to cancers, $X.X use market metastatic combination uptake grew from combination KEYTRUDA In cell price across well cancer as practice and by growth. brands. driven in robust KEYTRUDA disease, well increased was by continued with U.S., cancer. Outside in increased increases first-line KEYTRUDA consistent well the supported the Inflation-related the global oncology, early-stage cancer, in saw driven setting, also strong In to contributed of with driven by from KEYTRUDA on grew chemotherapy breast for as increased we endometrial growth uptake cancer in tumor cancer data key from results earlier-stage demand in the Padcev metastatic key with locally urothelial types. in
uptake including driven achieved in increased with portfolio double-digit pneumococcal, China. by price by Japan. and overall in was purchasing were retail offset million pharmacy demand, GARDASIL of $X.X In with $XXX certain CDC billion, CAPVAXIVE doubling higher the to sales patterns.
Outside from benefited In $XX partially carcinoma oncology vaccines, catch-up broader and sales Our cell growth to more U.S. the strong in the growth, by sales decrease in due the lower sales treated cohort sales demand U.S., from were previously WELIREG, demand, the patients In U.S. million China, driven driven demand than XX%, a advanced including renal by channel.
of to received and commercial contributed majority was the the new those are sales, to as of our prescribed some physicians bringing $XXX Access steady international commercial we to remain product.
Notably, of the the they U.S., to more ensure in positioned who The number great in launch. continues holiday by treatment. X,XXX from remains and at to we Approximately X,XXX launch in than strong, competitive patients prescription grow. the million seeing adults made continues a patients invasive the in help of is successful ongoing to to offset progress prescription have due are saw that XX% see to season. milestones which growth patients from the well sales breadth indicate We approximately U.S. of on we where which U.S. new prescribe a pneumococcal since experience patients total approximately depth volumes vast will a receive cardiovascular, launch continue and prescription, achieving protect receive WINREVAIR, pressures necessary decreased of impact X% growth disease.
VAXNEUVANCE the predominantly in markets from In
We growth prostacyclin In are are percentage with well. WINREVAIR in increase as an our on summary, pulmonary patients the initial to U.S., in background of for look impacting patients confident we the forward prescriptions for therapy. more remain hypertension. also positively Outside arterial expectations seeing progressing launches not we
you walk percentage growth acquired recently sales margin aqua increasing the the Sales rates and Hansa Charges Health of portfolio of this quarter growth and reflects an points, reflects Daiichi comments favorable driven Animal Gross from to Operating related to Elanco was as price.
I be royalty will $X.X license GARDASIL were higher the increase growth another with demand now Companion my $X.X on than XX%. and a million Livestock $XXX sales well will strong Sankyo. of of basis. ago from related LaNova KEYTRUDA business a year for as through expenses animal reduced Our with the with X.X for poultry. charge agreements price. the billion. product remainder lower to P&L, decreased our delivered non-GAAP by XX.X%, mix. Pharma quarter billion of collaboration
strategic of million. drivers. early- pipeline XX%, and charges, grew robust growth and investments operating Other expenses key reflecting our these in was expense support late-phase $X Excluding
XX.X%. was rate tax Our
per earnings share together, were Taken $X.XX.
non-GAAP guidance. our turning Now XXXX to
We billion, mid-January ], excluding of million [ expect a foreign to to X% up be impact exchange revenue between growth approximately using from negative rates. $XX.X and representing X% $XX.X
than high further the in less billion no For assumes GARDASIL at and guidance end. at shipments $X low our the China, end
Excluding and be sales in company X%. XXXX in exchange, of to GARDASIL and foreign is both growth X% expected impact XXXX negative from China total the to
assumed be approximately the $XX.X MK-XXXX. the of is transfer Our are $XX.X be recognized includes between license assumption gross for billion completion agreement and million related LaNova, range expenses to payment which upon billion. margin XX.X% This a will to technology $XXX with Operating
] expected development million.
We transactions. assume not As year our and XX% expense does outstanding. XX%. $XXX tax significant a assume billion approximately is guidance business to X.XX Other We and million shares be a additional full between rate $XXX between [ assume potential reminder,
expected $X.XX Taken expect impact approximately This $X.XX of foreign from mid-January of to $X.XX approximately to ]. exchange negative payment to [ includes EPS and together, LaNova the $X.XX rates. using a range related we
product few launches. diverse well a Health expecting mind. items consider you new and as from there to are are As your the Animal in models, In we as contributions continued keep commercial of with strength see benefit a to portfolio oncology in XXXX, more
During offset half digits the our of high roughly single as first rest is ] across business. the the of in by year, year-over-year flat the [ revenues headwind expect we China
the strong expect During second year-over-year we half, growth.
at longer Looking term. GARDASIL
believe there we given prudent feel this the timing economic billion, withdraw to be in China. we to While $XX target a of is path recovery continues uncertain an it to
Our are well vaccine China important for growth unchanged drive and positioned more lives to and remain protect growth this of expectations outside we XXXX. and beyond strong
from U.S. inventory approximately we reverse buy-in during $XXX first of the quarter, fourth to sales benefited For wholesaler KEYTRUDA, expect in million the quarter. which
Medicaid. the expect Part approximately of of WELIREG, oncology to prices to with beginning them the lowered and net the D sales we to list WINREVAIR JANUVIA our Lynparza net The of We $XXX to impact as and XXXX. in redesign affecting portfolio a rebate higher list Lenvima.
At Medicare small U.S. prices. reduce of amount million, a for in of negative primarily will lower align closely products products, pays have we molecule the sales family XXXX, And these including result, Merck expect price the more
Now turning to our capital remains strategy allocation, unchanged. where
We will long-term prioritize drive growth. and near- in to our business investments
Business We for repurchases our and goal pipeline. recently a science-driven, with time. committed drivers to pursue [indiscernible] to increase of additional expansive $XX remains remain positioned growth share dividend and total. well to $XX will billion make are the our to key billion transactions.
We it authorization investments by priority, in to continue disciplined in we increased our value-enhancing We over development
expect through to modest a build our not this our we demand exceptional as innovative Given to our confidence in vaccines the XXXX year. and We outlook the of sheet, augment we flexibility pipeline. conclude, and maintain business pipeline business as opportunities increase development, having our on in entered repurchases to level remain committed share excess higher and our cash to global provides for repurchases balance by appropriate.
To authorization the with our business share for if well medicines driven invest
innovation improve to patients we to now position now the to call well a leading leverage in us operational to of shareholders to our focus With has ongoing over into and clients commitment strength. patients, Dean. and the are I'd execution, long-standing value in like customers Our deliver and lives turn financial future.
With on the well and put to positioned investment of that,
